This founding underlines the importance of less-invasive assay of serum CCL18 in clinical management setting, which is more superior to other cancer biomarkers assayed via immunohistochemistry or qPCR in cancer tissue biopsy or surgery. This evidence concerns the gene CCL18 and cancer.